Medicine
Aphexda 62 mg/1.7 mL powder for injection
Aphexda 62 mg/1.7 mL powder for injection is a prescription medicine containing Motixafortide for subcutaneous use, marketed by BioLineRx, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store at 2°C to 8°C (36°F to 46°F) in original carton to protect from light…
Key facts
- Active ingredient (INN)
- Motixafortide
- Brand
- Aphexda
- Strength
- 62 mg/1.7 mL
- Dosage form
- Powder for injection
- Route
- Subcutaneous
- Packs
- 1 vial
- Marketing authorisation holder
- BioLineRx
- Manufacturers
- BioLineRxGamida Cell
- Origin register
- US FDA, United States
- Storage
- Store at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Discard prepared reconstituted solution after 24 hours storage under refrigeration 2°C to 8°C (36°F to 46°F) or at room temperature 20°C to 25°C (68°F to 77°F) protected from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 September 2023
- Identifiers
- RxCUI 2664901, 2664906DailyMed set ID e704b2db-f119-40ba-9346-9229e3281c9e, f7cdc584-ebf0-a68e-e053-6294a90a9ea9NDC 73441-062, 82737-073Application NDA217159
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 1.7 mL in 1 vial, glass | 82737-073-01 | BioLineRx | 8 September 2023 |
| 1 vial, glass in 1 carton / 1.7 mL in 1 vial, glass | 73441-062-01 | Gamida Cell | 15 June 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 8 September 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Motixafortide is a prescription medicine indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. MedsAcross supplies Motixafortide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MotixafortideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Aphexda prescribing information (BioLineRx) · U.S. National Library of Medicine, DailyMed
Need Aphexda 62 mg/1.7 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.